These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3437067)

  • 1. The disposition of recainam hydrochloride during and after intravenous loading and maintenance infusion in cardiac patients.
    Hampton EM; Anastasiou-Nana MI; Nanas JN; Nappi JM; Capuzzi DM; Anderson JL
    J Clin Pharmacol; 1987 Dec; 27(12):951-6. PubMed ID: 3437067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.
    Anderson JL; Reddy CP; Myerburg RJ; Waxman HL; de Vane PJ
    Am J Cardiol; 1993 Mar; 71(8):686-94. PubMed ID: 8447266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.
    Troy SM; Cevallos WH; Conrad KA; Chiang ST; Latts JR
    J Clin Pharmacol; 1991 May; 31(5):433-9. PubMed ID: 2050828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical electrophysiological effects of intravenous recainam: an antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias.
    Feld GK; Luceri RM; Greenspon AJ; Singh BN; Horowitz LN; Capuzzi DM; Frame VB; Myerburg RJ
    Pacing Clin Electrophysiol; 1991 Jul; 14(7):1129-37. PubMed ID: 1715550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias.
    Davies RF; Lineberry MD; Funck-Brentano C; Echt DS; Lee JT; Capuzzi DM; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1989 Sep; 46(3):324-34. PubMed ID: 2673622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac electrophysiology of the antiarrhythmic agent recainam (Wy-42,362) in anesthetized dogs: relation to plasma and myocardial concentrations.
    Colatsky TJ; Bird LB; Knowles JA
    J Cardiovasc Pharmacol; 1988 Mar; 11(3):308-16. PubMed ID: 2452923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of recainam, a new antiarrhythmic drug, for control of ventricular arrhythmias.
    Anderson JL; Anastasiou-Nana MI; Heath BM; Menlove RL; Nanas JN; Friedman J
    Am J Cardiol; 1987 Aug; 60(4):281-7. PubMed ID: 2441587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
    Cheng JW; Charland SL; Goldfarb S; Spinler SA
    Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recainam, a potent new antiarrhythmic agent: effects on complex ventricular arrhythmias.
    Anastasiou-Nana MI; Anderson JL; Hampton EM; Nanas JN; Heath BM
    J Am Coll Cardiol; 1986 Aug; 8(2):427-35. PubMed ID: 3734265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia.
    Tai YT; Campbell RW; McComb JM
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):310-5. PubMed ID: 1709237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug.
    Scatina JA; Kimmel HB; Weinstein V; Troy SM; Sisenwine SF; Cayen MN
    Biopharm Drug Dispos; 1990 Jul; 11(5):445-61. PubMed ID: 2207297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes.
    Frame LH; Sheldon JH
    J Am Coll Cardiol; 1988 Sep; 12(3):746-52. PubMed ID: 3403835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular electrophysiology of the new antiarrhythmic agent recainam (Wy-42,362) in canine cardiac Purkinje fibers.
    Colatsky TJ; Bird LB; Jurkiewicz NK; Wendt RL
    J Cardiovasc Pharmacol; 1987 Apr; 9(4):435-44. PubMed ID: 2438506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excretion and metabolism of recainam, a new anti-arrhythmic drug, in laboratory animals and humans.
    Scatina JA; Wells DS; Kimmel HB; Kemper CJ; Sisenwine SF
    Drug Metab Dispos; 1990; 18(5):746-52. PubMed ID: 1981731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
    Tisdale JE; Overholser BR; Sowinski KM; Wroblewski HA; Amankwa K; Borzak S; Kingery JR; Coram R; Zipes DP; Flockhart DA; Kovacs RJ
    Pharmacotherapy; 2008 Dec; 28(12):1461-70. PubMed ID: 19025427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic effects and efficacy of recainam for sustained ventricular tachycardia.
    de Buitleir M; Kou WH; Nelson SD; Schmaltz S; Morady F
    Am J Cardiol; 1989 Jan; 63(1):116-8. PubMed ID: 2642366
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction.
    Feld GK; Venkatesh N; Singh BN
    J Cardiovasc Pharmacol; 1988 May; 11(5):573-80. PubMed ID: 2455844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
    Le Coz F; Funck-Brentano C; Morell T; Ghadanfar MM; Jaillon P
    Clin Pharmacol Ther; 1995 May; 57(5):533-42. PubMed ID: 7768076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug.
    Pavlou HN; Funck-Brentano C; Lineberry MD; Woosley RL; Roden DM
    Clin Pharmacol Ther; 1991 Mar; 49(3):314-21. PubMed ID: 2007325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.